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Abstract
Background: Secondary mitral insufficiency (SMI) is an indicator of a poor prognosis in patients
with ischemic and dilated cardiomyopathies. Numerous studies corroborated that mitral valve
(MV) surgery improves survival and may be an alternative to heart transplantation in this group of
patients.
The aim of the study was to retrospectively analyze the early and mid-term clinical results after MV
repair resp. replacement in patients with moderate-severe to severe SMI and left ventricular
ejection fraction (LVEF) below 35%.
Methods: We investigated 40 patients with poor LVEF (mean, 28 ± 5%) and SMI who underwent
MV repair (n = 26) resp. replacement (n = 14) at the University Hospital Muenster from January
1994 to December 2005. All patients were on maximized heart failure medication. 6 pts. had prior
coronary artery bypass grafts (CABG). Twenty-seven patients were in New York Heart
Association (NYHA) class III and 13 were in class IV. Eight patients were initially considered for
transplantation. During the operation, 14 pts had CABG for incidental disease and 8 had tricuspid
valve repair. Follow-up included echocardiography, ECG, and physician's examination and was
completed in 90% among survivors. Additionally, the late results were compared with the survival
after orthotope heart transplantation (oHTX) in adults with ischemic or dilated cardiomyopathies
matched to the same age and time period (148 patients).
Results: Three operative deaths (7.5%) occurred as a result of left ventricular failure in one and
multiorgan failure in two patients. There were 14 late deaths, 2 to 67 months after MV procedure.
Progress of heart failure was the main cause of death. 18 patients who were still alive took part on
the follow-up examination. At a mean follow-up of 50 ± 34 (2–112) months the NYHA class
improved significantly from 3.2 ± 0.5 to 2.2 ± 0.4 (p < 0.001). The LVEF improved significantly from
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29 ± 5% to 39 ± 16 (p < 0.05). There were no differences in survival after MV repair or
replacement. The 1-, 3-, 5-year survival rates in the study group were 80%, 58% and 55%
respectively. In the group of patients after oHTX the survival was accordingly 72%, 68%, 66% (p >
0.05).
Conclusion: High risk mitral valve surgery in patients with cardiomyopathy and SMI offers a real
mid-term alternative method of treatment of patients in drug refractory heart failure with similar
survival in comparison to heart transplantation.
Mitral valve insufficiency associated with a considerably
impaired left ventricular (LV) function is not a homogene-
ous clinical entity. On the one hand, it could be a compo-
nent of the mitral valve disease itself as a primary
insufficiency. On the other hand, it could be secondary or
functional as a manifestation of a late stage of different
forms of heart pathology such as dilated cardiomyopathy
and ischemic heart disease. In patients with end-stage car-
diomyopathy secondary mitral insufficiency (SMI) occurs
in approximately 60% and is associated with a poor prog-
nosis [1-3]. Myocardial damage by infarction or from
dilated cardiomyopathy leads to leakage of the anatomi-
cally normal MV. Following dilatation of the annular-ven-
tricular apparatus, papillary muscle displacement, and an
altered ventricular geometry, left ventricular volume over-
load occurs which decreases leaflet coaptation and wors-
ened mitral regurgitation [4,5]. Due to increased risk for
perioperative death and presumably worse long-term
results some authors recommended conservative treat-
ment in patients with SMI and severe left ventricular dys-
function [6]. In a review of this cohort 1-year mortality
after diagnosis of SMI has been reported between 34%
and 70% [7-10]. It has been shown that 50% of these
patients die within 3 years after first admission to the hos-
pital without surgical treatment [10].
For cardiomyopathy with SMI, heart transplantation was
the treatment of choice in most institutions, since mitral
valve surgery in patients with severe heart failure had been
identified as an indicator of poor prognosis in numerous
studies [11-13]. Although, cardiac transplantation has
encouraging results for these patients with SMI and end-
stage heart failure, transplantation is hindered by donor
organ shortage and its limited applicability to older
patients or those with concurrent diseases.
Along with the increasing shortage of appropriate donor
organs and improved surgical techniques, various con-
cepts of high risk mitral valve surgery evolved. Studies
could show improved exercise capacity following mitral
valve operation in these patients [14,15]. It was shown
that end-diastolic and end-systolic dimensions and vol-
umes were lessened and stroke volume and ejection frac-
tion increased [3,16,17]. We have previously reported on
our experience with high risk mitral valve surgery -in
patients with severe left ventricular dysfunction [18]. The
aim of this paper is to analyze the mid-term outcome and
the cause of late death in this patient group. Furthermore
we evaluated from our late results if MV repair or replace-
ment have influence on survival. In addition we com-
pared these results with the late results after heart
transplantation in an age, gender and time-period
matched patient group.
Patients and methods
From January 1994 to December 2005, 40 consecutive
patients with SMI (grade III-IV) and impaired left ven-
tricular pump function (EF < 35% in echocardiography
and angiography) underwent mitral valve surgery at our
institution. Patients with previous coronary artery bypass
grafting (CABG) were included in the study; patients with
an additional left ventricular remodeling procedure were
excluded.
The study population included 20 male and 20 female
patients with a mean age of 64 ± 9 years. 26 patients suf-
fered from dilative cardiomyopathy, 14 from ischemic
cardiomyopathy. Mean preoperative ejection fraction was
28 ± 5%. 24 had chronic atrial fibrillation. 27 patients
were in New York Heart Association (NYHA) class III and
13 patients in NYHA class IV despite optimized heart fail-
ure therapy which typically included digoxin, angiotensin
– converting enzyme inhibitors, diuretics, beta – blockers
and spironolactone. 16 patients had been initially referred




Age (years) 64 ± 9
NYHA class 3.3 ± 0.5
Atrial fibrillation 24 (60%)
Creatinine > 1.5 mg/dl 27 (67.5%)
History of stroke 6 (15%)
Data presented as mean ± SD and total number
NYHA = New York Heart AssociationJournal of Cardiothoracic Surgery 2009, 4:36 http://www.cardiothoracicsurgery.org/content/4/1/36
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to our institution for evaluation of heart transplantation.
Patient characteristics and comorbidities are shown in
Table 1.
All patients underwent transthoracic or transoesophageal
echocardiography on hospital admission, transoesopha-
geal echocardiography after induction of anesthesia prior
to sternotomy and intraoperative to control the results
after mitral valve surgery. Postoperative follow-up
echocardiography was obtained prior to discharge and on
follow-up. If no follow-up was available in our institution
(two patients), the investigation was performed at a city
hospital.
The perioperative measurement of left ventricular cham-
ber size at end-diastole and end-systole as well as the
assessment of mitral regurgitation were performed by
transthoracic two-dimensional echocardiographic images
in the parasternal long-axis view (including M-mode) and
by apical four-chamber view. The intraoperative analysis
was performed by employing short-axis and long-axis
views using a transoesophageal approach. Left ventricular
volumes and ejection fraction were calculated by modifi-
cation of Simpson's rule method with two apical views.
Stroke volume was calculated as the difference between
the diastolic and systolic volumes, and ejection fraction
was calculated as the ratio of stroke volume to end-diasto-
lic volume. Colour Doppler flow mapping of regurgitant
jets with visualisation of the vena contracta and proximal
isovelocity surface area was used for quantification of val-
vular regurgitation. The severity was graded as mild (I),
moderate (II), moderate-severe (III), and severe (IV)
[3,19].
29 patients (72.5%) had grade 3, and 11 (27.5%), grade 4
mitral regurgitation. All patients had normal or moderate
impaired right ventricular function without presence of
liver failure, although in 10 patients the mean pulmonary
pressure was higher than 40 mm Hg.
Preoperative echocardiography and hemodynamic data
are listed in Table 2.
Surgical Procedure
Mitral valve surgery was performed through a median ster-
notomy, establishing a cardiopulmonary bypass with a
moderate systemic hypothermia. Myocardial protection
was administered using an intermittent retrograde cold
blood cardioplegia and topical cooling in all patients. The
operative data are outlined in Table 3. The MV was
exposed through the interatrial septum only or through
left atrial roof and interatrial septum. 26 patients under-
went mitral valve repair, 12 of whom had a quadrangular
resection of the posterior leaflet (P2), and six had com-
missural plasties according to Whooler (n = 2) or Kay (n
= 4). No chordal transfer or Alferi stitch was performed in
this patient group. In all patients, a moderately under-
sized Carpentier Edwards classic annuloplasty ring (28 –
30 mm) was inserted as a part of the repair, even after Kay
or Whooler commissural plasties [20].
Mitral valve replacement was unavoidable in 14 patients.
A Carpentier Edwards bioprosthesis was implanted in
nine patients, and a mechanical St. Jude Medical valve in
five patients. All efforts were made to preserve the poste-
rior leaflet with the subvalvular apparatus.
Table 2: Echocardiography and right heart catheter data
Variable
LVEDD (mm) 65 ± 7
LVESD (mm) 47 ± 8
LVEDV (ml) 191 ± 67
LVESV (ml) 118 ± 53
LVEDP (mmHg) 23 ± 8
SV (ml) 53 ± 17
LVEF (%) 28 ± 5
V – Wave (mmHg) 43 ± 14
Pulmonary artery systolic pressure (mmHg) 55 ± 14
Pulmonary artery diastolic pressure (mmHg) 26 ± 9
Mean pulmonary artery pressure (mmHg) 35 ± 11
Pulmonary capillary wedge pressure (mmHg) 23 ± 6
Mitral regurgitation (grade) 3.2 ± 0.4
Cardiac index (L/min/m2) 2.0 ± 0.3
Data presented as mean ± SD
LVEDD = left ventricular end-diastolic diameter; LVESD = left 
ventricular end-systolic diameter; LVEDV = left ventricular end-
diastolic volume; LVESV = left ventricular end-systolic volume; LVEDP 
= left ventricular end-diastolic pressure; SV = stroke volume; LVEF = 
left ventricular ejection fraction.
Table 3: Operative data
Variable
OP Duration 181 ± 46
X-clamp (minutes) 51 ± 23
CPB time (minutes) 111 ± 40
Mitral valve repair 26
Isolated 14
+ Tricuspid valve repair 4
+ CABG 7
+ Tricuspid valve repair + CABG 1
Mitral valve replacement 14
Isolated 5




Data presented as mean ± SD and total number
X – clamp = cross-clamping time; CPB = cardiopulmonary bypass; 
CABG = coronary artery bypass graftingJournal of Cardiothoracic Surgery 2009, 4:36 http://www.cardiothoracicsurgery.org/content/4/1/36
Page 4 of 7
(page number not for citation purposes)
Fourteen patients underwent a combined procedure with
additional coronary artery bypass grafting (CABG) which
was performed first, using the mammary artery in all cases
and if necessary a saphenous vein graft (mean, 2 ± 1 distal
anastomoses).
An additional tricuspid valve annuloplasty was performed
in 8 patients after MV surgery. A De Vega procedure was
used in 6 patients and an annuloplasty ring in 2 patients.
Follow-up
In 34 (92%) from 37 patients, who were discharged from
the hospital after operation, mid-term results were ana-
lyzed. 14 patients died during follow-up. 20 patients were
still alive and complete follow-up was available. All
patients were interviewed by telephone, and were invited
to an examination on an ambulatory basis. 18 patients
agreed to participate on the follow-up examination at our
institution. Two patients underwent follow-up examina-
tion at other institutions.
Statistics
The paired Student t-test was used to compare groups. The
log rank test was used in the Kaplan-Meier Survival analy-
sis. Data are expressed as mean ± SD. A p-value of less than
0.05 was considered statistically significant.
Results
Operative mortality and morbidity
Postoperative data with duration of mechanical ventila-
tion, ICU treatment, complications and hospital stay are
listed in Table 4. All patients required moderate or high
dose inotropic treatment to wean from cardiopulmonary
bypass. In ten patients (25%) an intraaortic balloon
pump (IABP) was inserted, in 9 patients intraoperatively
to facilitate termination of cardiopulmonary bypass and
in one for perioperative myocardial infarction.
Three patients (7.5%) died within thirty days after sur-
gery. One patient died 1 day after MV replacement and
CABG following acute myocardial infarction. One death
occurred 10 days postoperatively as a consequence of
severe right ventricular dysfunction and secondary multi-
organ failure. The other patient died in a septic shock on
day 28. Mean intensive care unit stay was 2.5 ± 4.7 days.
Mean hospital stay was 8.8 ± 4.7 days.
Two patients (5%) required operative re-exploration
because of bleeding.
Three patients needed readmission in the ICU for acute
respiratory insufficiency. Furthermore, three patients with
preoperative renal impairment needed dialysis postopera-
tively for acute renal failure. In 2 patients (5%) an ICD
was implanted due to ventricular tachycardia.
Follow-up results
Follow-up data were completed in March 2007. There
were 14 late deaths during the follow-up period, 2 to 67
month after MV procedure (Table 5). Eight patients died
related to cardiac reasons (heart failure = 7, sudden death
= 1). There were no differences in late mortality for
ischemic or dilated cardiomyopathy in these 8 patients.
The other five patients died from not heart failure-related
causes: pneumonia with sepsis in two cases, stroke, cere-
bral bleeding and cancer complicated with intestine per-
foration in one patient. In one patient the cause of death
was unknown. After a follow-up period of 50 ± 34 months
(range, 2–112 month), mean NYHA functional class sig-
nificantly improved from 3.3 ± 0.5 at operation to 2.2 ±
0.4 (p < 0.001). There were no differences between
ischemic or dilated cardiomyopathy patients. A late
echocardiographic study (62 ± 29 months) was available
in 18 cases and only echocardiographic examinations per-
formed at our institution were included (Table 6). The left
ventricular ejection fraction had increased from 29 ± 4%
to 39 ± 16% at follow-up (p < 0.05). The mitral valve
regurgitation severity decreased significant from Grade








Postoperative bleeding (mL) 854 ± 618
Redo for bleeding 2 (5%)
Transient psychosis 4 (10%)
Ventilation (hours) 16.9 ± 14.9
ICU stay (days) 2.5 ± 4.7
Ventrical tachycardia 2 (5%)
Sternal infection 1 (2.5%)
Hospital stay (days) 8.8 ± 4.7
Data presented as mean ± SD and total number
AMI = acute myocardial infarction; IABP = intraaortic balloon pump; 
ICU = intensive care unit.
Table 5: The cause of late death
Mortality No of pts
Total deaths (2 to 67 months) 14
Progress of heart failure (3,4,6,16,31,34,56,67 months) 7
Sudden death (9 months) 1
Pneumonia with sepsis (25 and 27 months) 2
Stroke (26 months) 1
Intestine perforation, peritonitis (2 months) 1
Cerebral bleeding (17 months) 1
Unknown (30 months) 1Journal of Cardiothoracic Surgery 2009, 4:36 http://www.cardiothoracicsurgery.org/content/4/1/36
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3.2 ± 0.4 to moderate regurgitation Grade 1.5 ± 0.4 at fol-
low-up (p < 0.001). The left ventricular end-diastolic
diameter decreased from 64 ± 5 to 60 ± 7 mm (p = 0.062)
and the echocardiographic parameters of systolic pulmo-
nary artery pressure and pulmonary capillary wedge pres-
sure show a significant reduction of pulmonary
hypertension (p < 0.01).
The 1-, 3-, 5-year survival rates in the study group were
80%, 58% and 55% respectively. There were no differ-
ences in survival after MV repair or replacement (Fig. 1).
Additionally we have compared the late results in the
study group with the survival after cardiac transplantation
in 148 age, gender and time-period matched patients with
dilated and ischemic cardiomyopathy (Fig. 2). In this
group the survival was accordingly 72%, 68%, 66% and
similar to patients after MV surgery (p > 0.05).
From ten patients with preoperative pulmonary hyperten-
sion with mean pulmonary pressure higher 40 mmHg
three patients died owing to progressive heart failure, six
were still alive at time of follow-up examination (range 53
– 100 month) and in one patient was lost to follow-up.
Discussion
Surgical treatment in patients with SMI and considerably
impaired LV function had been identified as an indicator
of poor prognosis. This is due to the primary ventricular
problem that causes MV dysfunction and, despite of the
SMI correction, the disease further exists [21]. MV surgery
is associated with a high mortality which in the series of
other investigators varies between 2.3% and 19.4%
[3,16,22]. The patients in our study, therefore, repre-
sented a high predicted mortality among patients with
dilated or ischemic cardiomyopathy. The surgical mortal-
ity in patients with ischemic cardiomyopathy with an age
> 60 years have been reported from 10 to 48% [23]. A high
operative mortality of 21% has been reported among a
group of 28 patients undergoing mitral valve replacement
and additional CABG [24]. Despite high operative risks
the 30-days mortality in our group of patients was moder-
ate with 7.5% (n = 3). All patients with early death had
ischemic cardiomyopathy with previous CABG. In addi-
tion, in two cases it was a combination of MV replacement
with CABG and in one a combination of MV repair, CABG
and TV repair. Redo's and prolonged cross-clamping times






LVEDD (mm) 64 ± 5 60 ± 7 0.062
LVEDV (ml) 185 ± 37 166 ± 61 0.298
LVEDP (mmHg) 25 ± 6 19 ± 5 0.122
EF (%) 29 ± 4 39 ± 16 0.038
PAs (mmHg) 58 ± 13 41 ± 9 0.001
PCWP (mmHg) 26 ± 6 17 ± 5 0.007
Mitral regurgitation (grade)* 3.3 ± 0.4 1.5 ± 0.4 0.001
Cardiac index (L/min/m2) 2.1 ± 0.3 2.4 ± 0.5 0.195
NYHA 3.2 ± 0.5 2.2 ± 0.4 0.001
Data presented as mean ± SD
*Only in patients with mitral valve repair (n = 13).
LVEDD = left ventricular end-diastolic diameter; LVEDV = left 
ventricular end-diastolic volume; LVEDP = left ventricular end-
diastolic pressure; LVEF = left ventricular ejection fraction; PAs = 
systolic pulmonary artery pressure;. PCWP = pulmonary capillary 
wedge pressure; NYHA = New York Heart Association:
Kaplan – Meier survival curve in patients after MV recon- struction and MV replacement Figure 1
Kaplan – Meier survival curve in patients after MV 
reconstruction and MV replacement. Log Rank 0.541.
Kaplan – Meier survival curve in patients after MV surgery  (MVR) and heart transplantation (HTX) Figure 2
Kaplan – Meier survival curve in patients after MV 
surgery (MVR) and heart transplantation (HTX). Log 
Rank 0.426.Journal of Cardiothoracic Surgery 2009, 4:36 http://www.cardiothoracicsurgery.org/content/4/1/36
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are the mainly responsible for the high mortality in
patients with -ischemic cardiomyopathy. There were no
deaths in patients with dilated cardiomyopathy and our
results confirm the reports of other authors about poor
early outcomes in patients with ischemic cardiomyopa-
thy.
MV surgery in patients with LV dysfunction is associated
with higher postoperative complication rates. Two thirds
of our patients had preoperative atrial fibrillation and/or
compensated renal insufficiency and ten of them were
older than 70 years. Postoperative morbidity rate
exceeded 40% and was expected in this cohort of patients
with serious comorbidities. Early complications such as
redo for bleeding, acute respiratory failure, acute renal
failure with dialysis and ventricular tachycardia developed
in 11 (27.5%) of our patients. This is the reason for longer
ventilation, ICU- and hospital stay and that coincides
with reports of other investigators [3,25].
All patients showed improvement in exercise tolerance at
the follow-up, and the NYHA class improved significantly.
There were no differences between patients with ischemic
or dilated cardiomyopathy. Quantitative echocardio-
graphic analyses showed a markedly increase of ejection
fraction, a significant reduction of pulmonary hyperten-
sion and of the left ventricular end-diastolic diameter at
follow-up. Furthermore six from ten patients (60%) with
severe pulmonary hypertension were still alive (mean sur-
vival 58 ± 29 months) at time of follow-up. These results
do not confirm the opinion of other investigator about
poor outcomes in this cohort of patients [26]. The mitral
regurgitation improved significantly from severe to mod-
erate at follow-up in the repair/annuloplasty group. The
mid-term survival in this study group was none signifi-
cantly shorter compared to heart transplantation.
Following the guidelines for the management of patients
with valvular heart disease asymptomatic patients with an
ejection fraction below 60% and/or end-systolic dimen-
sion over 40 mm and symptomatic patients with EF above
30% and LVESD below 55 mm are candidates for mitral
surgery [27]. Still controversy exists regarding the opera-
tion (MVR versus HTX) in patients with severe reduced
ejection fraction.
Our results could show that MV surgery in patients with
considerably impaired LV function has a similar mid-term
outcome compared to transplantation. We therefore con-
clude that in MV surgery is an acceptable alternative pro-
cedure which improved quality of life in the present time
with increasing organ shortage.
Of importance is the preservation of the mitral valve appa-
ratus. Previous clinical studies have compared the results
of MV reconstruction against those following MV replace-
ment and have concluded that preservation of the annu-
lar-chordal-papillary muscle continuity results in
maintenance of LV function and geometry, leading to bet-
ter patient outcome [28-30]. However, we could not
observe a difference in outcome between MV repair and
replacement. One reason could be the preservation of the
mitral valve apparatus despite MV replacement, which
was observed in our studies, too [31]. But we think that
chordal sparing mitral valve replacement is not a better
way to treat SMI because of the need for anticoagulation
for mechanical prosthesis in mitral position and inevita-
ble degeneration of bioprosthesis.
Through the restoration of the mitral competency and
ventricular geometry, MV surgery offers a new treatment
strategy for the treatment of end-stage heart failure.
Limitations of the study
This study has several limitations. First, the population
represents a relatively small number of patients. However,
significant differences were detected. Second, the accuracy
of the volume quantification is dependent to operator
experience, and calculation of flows has inherent errors
because of limitations in measurement accuracy. Third,
the assessment for the functional status at the follow-up
was subjective. We tried to objective our results using
standardized exercise tests. Forth, the comparison of the
mitral valve with the transplant patient group is not very
accurate, because of the more depressed LV function and
co-morbidities in the transplant group. However, we tried
to overcome this obstacle by age, gender and time period
matching.
Conclusion
High risk mitral valve surgery for secondary mitral regur-
gitation in patient with ischemic and dilated cardiomy-
opathies and considerably impaired LV function corrects
effectively mitral regurgitation and represents an alterna-
tive procedure in a high-risk population with an accepta-
ble perioperative mortality rate. Decrease in mitral
regurgitation after surgical correction contributes to resto-
ration of left ventricular geometry and may be an alterna-
tive to heart transplantation in selected patients.
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